Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications.
The company is founded by the former founders of Prosensa and Sarepta and reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Leiden Bio Science Park
J.H. Oortweg 21
Leiden, 2333 BD
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.